Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis.
Mark C KorpicsWilliam Tyler TurchanMatthew KoshyMichael T SpiottoPublished in: Head & neck (2022)
Compared to chemoRT or RTonly, cetuxRT is associated with decreased OS for patients with HNSCC, suggesting minimal benefit of bioradiotherapy in this population.